Using bifidobacterium and propionibacterium strains in probiotic consortia to normalize the gastrointestinal tract

Detalhes bibliográficos
Autor(a) principal: Dyshlyuk,L. S.
Data de Publicação: 2024
Outros Autores: Milentyeva,I. S., Asyakina,L. K., Ostroumov,L. A., Osintsev,A. M., Pozdnyakova,A. V.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Biology
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1519-69842024000100288
Resumo: Abstract The gastrointestinal microflora regulates the body’s functions and plays an important role in its health. Dysbiosis leads to a number of chronic diseases such as diabetes, obesity, inflammation, atherosclerosis, etc. However, these diseases can be prevented by using probiotics – living microorganisms that benefit the microflora and, therefore, improve the host organism's health. The most common probiotics include lactic acid bacteria of the Bifidobacterium and Propionibacterium genera. We studied the probiotic properties of the following strains: Bifidobacterium adolescentis АС-1909, Bifidobacterium longum infantis АС-1912, Propionibacterium jensenii В-6085, Propionibacterium freudenreichii В-11921, Propionibacterium thoenii В-6082, and Propionibacterium acidipropionici В-5723. Antimicrobial activity was determined by the ‘agar blocks’ method against the following test cultures: Escherichia coli ATCC 25922, Salmonella enterica ATCC 14028, Staphylococcus aureus ATCC 25923, Pseudomonas aeruginosa B6643, Proteus vulgaris ATCC 63, and Listeria monocytogenes ATCC 7644. Moderate antimicrobial activity against all the test cultures was registered in Bifidobacterium adolescentis АС-1909, Propionibacterium jensenii В-6085, and Propionibacterium thoenii В-6082. Antioxidant activity was determined by the DPPH inhibition method in all the lactic acid strains. Our study indicated that some Propionibacterium and Bifidobacterium strains or, theoretically, their consortia could be used as probiotic cultures in dietary supplements or functional foods to prevent a number of chronic diseases.
id IIE-1_b86bac3a2d5c8b2f6624c5fcf8805f1c
oai_identifier_str oai:scielo:S1519-69842024000100288
network_acronym_str IIE-1
network_name_str Brazilian Journal of Biology
repository_id_str
spelling Using bifidobacterium and propionibacterium strains in probiotic consortia to normalize the gastrointestinal tractlactic acid bacteriabifidobacteriapropionic acid bacteriabiocompatibilityAbstract The gastrointestinal microflora regulates the body’s functions and plays an important role in its health. Dysbiosis leads to a number of chronic diseases such as diabetes, obesity, inflammation, atherosclerosis, etc. However, these diseases can be prevented by using probiotics – living microorganisms that benefit the microflora and, therefore, improve the host organism's health. The most common probiotics include lactic acid bacteria of the Bifidobacterium and Propionibacterium genera. We studied the probiotic properties of the following strains: Bifidobacterium adolescentis АС-1909, Bifidobacterium longum infantis АС-1912, Propionibacterium jensenii В-6085, Propionibacterium freudenreichii В-11921, Propionibacterium thoenii В-6082, and Propionibacterium acidipropionici В-5723. Antimicrobial activity was determined by the ‘agar blocks’ method against the following test cultures: Escherichia coli ATCC 25922, Salmonella enterica ATCC 14028, Staphylococcus aureus ATCC 25923, Pseudomonas aeruginosa B6643, Proteus vulgaris ATCC 63, and Listeria monocytogenes ATCC 7644. Moderate antimicrobial activity against all the test cultures was registered in Bifidobacterium adolescentis АС-1909, Propionibacterium jensenii В-6085, and Propionibacterium thoenii В-6082. Antioxidant activity was determined by the DPPH inhibition method in all the lactic acid strains. Our study indicated that some Propionibacterium and Bifidobacterium strains or, theoretically, their consortia could be used as probiotic cultures in dietary supplements or functional foods to prevent a number of chronic diseases.Instituto Internacional de Ecologia2024-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1519-69842024000100288Brazilian Journal of Biology v.84 2024reponame:Brazilian Journal of Biologyinstname:Instituto Internacional de Ecologia (IIE)instacron:IIE10.1590/1519-6984.256945info:eu-repo/semantics/openAccessDyshlyuk,L. S.Milentyeva,I. S.Asyakina,L. K.Ostroumov,L. A.Osintsev,A. M.Pozdnyakova,A. V.eng2022-05-02T00:00:00Zoai:scielo:S1519-69842024000100288Revistahttps://www.scielo.br/j/bjb/https://old.scielo.br/oai/scielo-oai.phpbjb@bjb.com.br||bjb@bjb.com.br1678-43751519-6984opendoar:2022-05-02T00:00Brazilian Journal of Biology - Instituto Internacional de Ecologia (IIE)false
dc.title.none.fl_str_mv Using bifidobacterium and propionibacterium strains in probiotic consortia to normalize the gastrointestinal tract
title Using bifidobacterium and propionibacterium strains in probiotic consortia to normalize the gastrointestinal tract
spellingShingle Using bifidobacterium and propionibacterium strains in probiotic consortia to normalize the gastrointestinal tract
Dyshlyuk,L. S.
lactic acid bacteria
bifidobacteria
propionic acid bacteria
biocompatibility
title_short Using bifidobacterium and propionibacterium strains in probiotic consortia to normalize the gastrointestinal tract
title_full Using bifidobacterium and propionibacterium strains in probiotic consortia to normalize the gastrointestinal tract
title_fullStr Using bifidobacterium and propionibacterium strains in probiotic consortia to normalize the gastrointestinal tract
title_full_unstemmed Using bifidobacterium and propionibacterium strains in probiotic consortia to normalize the gastrointestinal tract
title_sort Using bifidobacterium and propionibacterium strains in probiotic consortia to normalize the gastrointestinal tract
author Dyshlyuk,L. S.
author_facet Dyshlyuk,L. S.
Milentyeva,I. S.
Asyakina,L. K.
Ostroumov,L. A.
Osintsev,A. M.
Pozdnyakova,A. V.
author_role author
author2 Milentyeva,I. S.
Asyakina,L. K.
Ostroumov,L. A.
Osintsev,A. M.
Pozdnyakova,A. V.
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Dyshlyuk,L. S.
Milentyeva,I. S.
Asyakina,L. K.
Ostroumov,L. A.
Osintsev,A. M.
Pozdnyakova,A. V.
dc.subject.por.fl_str_mv lactic acid bacteria
bifidobacteria
propionic acid bacteria
biocompatibility
topic lactic acid bacteria
bifidobacteria
propionic acid bacteria
biocompatibility
description Abstract The gastrointestinal microflora regulates the body’s functions and plays an important role in its health. Dysbiosis leads to a number of chronic diseases such as diabetes, obesity, inflammation, atherosclerosis, etc. However, these diseases can be prevented by using probiotics – living microorganisms that benefit the microflora and, therefore, improve the host organism's health. The most common probiotics include lactic acid bacteria of the Bifidobacterium and Propionibacterium genera. We studied the probiotic properties of the following strains: Bifidobacterium adolescentis АС-1909, Bifidobacterium longum infantis АС-1912, Propionibacterium jensenii В-6085, Propionibacterium freudenreichii В-11921, Propionibacterium thoenii В-6082, and Propionibacterium acidipropionici В-5723. Antimicrobial activity was determined by the ‘agar blocks’ method against the following test cultures: Escherichia coli ATCC 25922, Salmonella enterica ATCC 14028, Staphylococcus aureus ATCC 25923, Pseudomonas aeruginosa B6643, Proteus vulgaris ATCC 63, and Listeria monocytogenes ATCC 7644. Moderate antimicrobial activity against all the test cultures was registered in Bifidobacterium adolescentis АС-1909, Propionibacterium jensenii В-6085, and Propionibacterium thoenii В-6082. Antioxidant activity was determined by the DPPH inhibition method in all the lactic acid strains. Our study indicated that some Propionibacterium and Bifidobacterium strains or, theoretically, their consortia could be used as probiotic cultures in dietary supplements or functional foods to prevent a number of chronic diseases.
publishDate 2024
dc.date.none.fl_str_mv 2024-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1519-69842024000100288
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1519-69842024000100288
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/1519-6984.256945
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Instituto Internacional de Ecologia
publisher.none.fl_str_mv Instituto Internacional de Ecologia
dc.source.none.fl_str_mv Brazilian Journal of Biology v.84 2024
reponame:Brazilian Journal of Biology
instname:Instituto Internacional de Ecologia (IIE)
instacron:IIE
instname_str Instituto Internacional de Ecologia (IIE)
instacron_str IIE
institution IIE
reponame_str Brazilian Journal of Biology
collection Brazilian Journal of Biology
repository.name.fl_str_mv Brazilian Journal of Biology - Instituto Internacional de Ecologia (IIE)
repository.mail.fl_str_mv bjb@bjb.com.br||bjb@bjb.com.br
_version_ 1752129891266985984